



Medicines & Healthcare products
Regulatory Agency



Public Assessment Report

Decentralised Procedures

Quetiapine 25mg film-coated tablets
Quetiapine 100mg film-coated tablets
Quetiapine 150mg film-coated tablets
Quetiapine 200mg film-coated tablets
Quetiapine 300mg film-coated tablets

(quetiapine fumarate)

Procedure Nos: UK/H/1228/001-5/DC

UK Licence No: PL 00289/1068-1072

Teva UK Limited

Lay Summary

Quetiapine 25 mg, 100 mg, 150 mg, 200 mg and 300 mg film-coated tablets (quetiapine fumarate)

This is a summary of the Public Assessment Report (PAR) for Quetiapine 25 mg, 100 mg, 150 mg, 200 mg and 300 mg film-coated tablets (PL 00289/1068-72; UK/H/1228/001-5/DC). These products will be referred to as Quetiapine tablets throughout this report, for ease of reading.

This summary explains how Quetiapine tablets were assessed and their authorisation recommended, as well as the conditions of use. It is not intended to provide practical advice on how to use Quetiapine tablets.

For practical information about using Quetiapine tablets, patients should read the package leaflet or contact their doctor or pharmacist.

What are Quetiapine tablets and what are they used for?

Quetiapine tablets are ‘generic medicines’. This means that they are similar to ‘reference medicines’, already authorised in the UK called Seroquel 25mg, 100mg, 150mg, 200mg and 300mg tablets (AstraZeneca UK Limited; PL 17901/0038, 0039, 0041, 0040 & 0088).

Quetiapine tablets can be used to treat several illnesses, such as:

- Bipolar depression: where patients feel sad, depressed, guilty, lack energy, lose their appetite or can't sleep.
- Mania: where patients may feel very excited, elated, agitated, enthusiastic or hyperactive or have poor judgment including being aggressive or disruptive.
- Schizophrenia: where patients may hear or feel things that are not there, believe things that are not true or feel unusually suspicious, anxious, confused, guilty, tense or depressed.

How do Quetiapine tablets work?

Quetiapine tablets contain the active ingredient quetiapine (as quetiapine fumarate). This belongs to a group of medicines called anti-psychotics. This medicine is thought to work by altering the effect of certain chemicals in the brain, called dopamine, serotonin, noradrenaline and acetylcholine. These chemicals have the effect of changing the behaviour, mood and emotions. Dopamine is the main chemical that these medicines have an effect on.

How are Quetiapine tablets used?

Quetiapine tablets are taken orally once or twice a day. The whole tablet should be swallowed with a drink of water, with or without food.

The starting dose will be decided by a doctor. However, the maintenance dose is usually between 150mg and 800mg depending on patient's illness and needs. This medicine should not be taken with a drink of grapefruit juice. As this may affect the way the medicine works.

The dose in elderly people and in patients with liver problems may be adjusted by a doctor.

Quetiapine tablets should not be used by children or adolescents aged under 18 years.

This medicine can only be obtained with a prescription from a doctor.

For further information on how Quetiapine tablets are used, please see the Summaries of Product Characteristics or the package leaflet available on the MHRA website.

How have Quetiapine tablets been studied?

Because Quetiapine tablets are generic medicines, studies in patients have been limited to tests to determine that they are bioequivalent to the reference medicines, Seroquel 25mg, 100mg, 150mg, 200mg and 300mg tablets. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the benefits and risks of Quetiapine tablets?

Because Quetiapine tablets are generic medicines and are bioequivalent to the reference medicines, Seroquel 25mg, 100mg, 150mg, 200mg and 300mg tablets, their benefits and risks are taken as being the same as the reference medicines, Seroquel 25mg, 100mg, 150mg, 200mg and 300mg tablets.

Why are Quetiapine tablets approved?

It was concluded that, in accordance with EU requirements, Quetiapine tablets have been shown to have comparable quality and to be bioequivalent to Seroquel 25mg, 100mg, 150mg, 200mg and 300mg tablets. Therefore, the view was that, as for Seroquel 25mg, 100mg, 150mg, 200mg and 300mg tablets, the benefits outweigh the identified risks.

What measures are being taken to ensure the safe and effective use of Quetiapine tablets?

A satisfactory pharmacovigilance system has been provided to monitor the safety of these products.

Other information about Quetiapine tablets

All member states agreed to grant marketing authorisations for Quetiapine tablets on 11 September 2008 (UK/H/1228/001-5/DC). A list of the member states that granted each strength of product is provided on page 6.

Marketing Authorisations were granted in the UK on 17 October 2008 (PL 00289/1068-72).

The full PAR for Quetiapine tablets follows this summary.

For more information about treatment with Quetiapine tablets, read the package leaflet, or contact your doctor or pharmacist.

This summary was last updated in October 2016.

Table of Contents

I	Introduction	Page 6
II	Quality aspects	Page 7
III	Non-clinical aspects	Page 10
IV	Clinical aspects	Page 10
V	User consultation	Page 12
VI	Overall conclusion, benefit/risk assessment and recommendation	Page 12
	Table of content of the PAR update for MRP and DCP	Page 23
	Annex – 1	Page 24

I Introduction

Based on the review of the data on quality, safety and efficacy, the Reference Member State (RMS) and Concerned Member States (CMS) considered that the application for Quetiapine 25mg, 100mg, 150mg, 200mg and 300mg film-coated tablets (PL 00289/1068-72, UK/H/1228/001-5/DC), are approvable.

Quetiapine film-coated tablets are indicated for the treatment of schizophrenia, and for moderate to severe manic episodes. Quetiapine has not been demonstrated to prevent recurrence of manic or depressive episodes.

The applications were submitted under Article 10.1 of Directive 2001/83/EC, as amended, so-called generic applications.

The applications were submitted through the Decentralised Procedure (DCP), with the UK as the RMS and the following as CMS countries:

UK/H/1228/001/DC

Belgium, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Luxemburg, Norway, Poland, Portugal, Republic of Ireland, Slovak Republic, Slovenia, Spain, Sweden and The Netherlands

UK/H/1228/02/DC

Belgium, Bulgaria, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Italy, Luxemburg, Norway, Poland, Portugal, Republic of Ireland, Slovak Republic, Slovenia, Spain and Sweden

UK/H/1228/03/DC

Denmark, Finland, Germany, Greece, Hungary, Italy, Malta, Portugal, Republic of Ireland, Slovak Republic and The Netherlands

UK/H/1228/04/DC

Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Luxemburg, Malta, Norway, Poland, Portugal, Republic of Ireland, Slovak Republic, Slovenia, Spain, Sweden and The Netherlands

UK/H/1228/05/DC

Belgium, Denmark, Estonia, Finland, Germany, Greece, Hungary, Italy, Lithuania, Luxemburg, Malta Norway, Poland, Portugal, Republic of Ireland, Slovak Republic, Slovenia, Spain, Sweden and The Netherlands

The applications refer to the reference products, Seroquel 25mg, 100mg, 150mg, 200mg and 300mg tablets (8 respectively), originally authorised to Zeneca Limited on 31 July 1997.

These reference licenses underwent changes of ownership to the current Marketing Authorisation Holder, AstraZeneca UK Limited (PL 17901/0038, 0039, 0041, 0040 & 008) on 25 June 2000. The innovator products have been authorised in the UK for more than 10 years, so the period of data exclusivity has expired.

Quetiapine tablets contain the active ingredient, quetiapine (as quetiapine fumarate), which is an atypical antipsychotic agent. Quetiapine and the active human plasma metabolite, *N*-desalkyl quetiapine interact with a broad range of neurotransmitter receptors. Quetiapine and *N*-desalkyl quetiapine exhibit affinity for brain serotonin 5-HT₂ and dopamine D₁ and D₂ receptors. Quetiapine exhibits a higher affinity for serotonin 5-HT₂ receptors in the brain than

it does for dopamine D₁ and D₂ receptors in the brain. Additionally, *N*-desalkyl quetiapine has high affinity at serotonin 5-HT₁ receptors. Quetiapine and *N*-desalkyl quetiapine also have high affinity at histaminergic and adrenergic α₁ receptors, with a lower affinity at adrenergic alpha₂-receptors. Quetiapine has no appreciable affinity at cholinergic muscarinic or benzodiazepine receptors.

Quetiapine is active in tests for antipsychotic activity, such as conditioned avoidance. It also blocks the action of dopamine agonists, measured either behaviourally or electrophysiologically, and elevates dopamine metabolite concentrations, a neurochemical index of D₂ receptor blockade. The extent to which the *N*-desalkyl quetiapine metabolite contributes to the pharmacological activity of Quetiapine in humans is not known.

No new non-clinical studies were conducted, which is acceptable given that the applications cross-refer to a product that has been licensed for over 10 years.

The application depends upon the bioequivalence study presented by the applicant comparing the test product, Quetiapine 25mg film-coated tablets, to the reference product Seroquel 25mg tablets (AstraZeneca, UK). The bioequivalence study was carried out in accordance with Good Clinical Practice (GCP).

The RMS has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for these product types at all sites responsible for the manufacture and assembly of these products. Evidence of compliance with GMP has been provided for the named manufacturing and assembly sites. For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites.

II Quality aspects

II.1 Introduction

The drug products are presented as film-coated tablets, each tablet containing 25mg, 100mg, 150mg, 200mg or 300mg of the active ingredient quetiapine (as quetiapine fumarate). Full descriptions of the individual tablets may be found by referring to the summary of product characteristics (SmPCs) / patient information leaflet (PIL).

Other ingredients consist of pharmaceutical excipients, namely calcium hydrogen phosphate dihydrate, lactose monohydrate, povidone K-25, microcrystalline cellulose, sodium starch glycolate (type A), colloidal anhydrous silica, and magnesium stearate making up the tablet core; and hypromellose, titanium dioxide (E171), and triacetin making up the film-coating. In addition; the film-coat of the 25mg and 100mg strength tablets also contains lactose monohydrate, iron oxide yellow (E172), and sunset yellow FCF aluminium lake (E110); the film-coat of the 150mg and 300mg strength tablets also contains lactose monohydrate and iron oxide yellow (E172); and the film-coat of the 200mg strength tablets also contains polydextrose and macrogol 8000. The entire film-coat for the 25mg and 100mg strength tablets, made up of the named constituents, is called Opadry II Lt Orange; the entire film-coat for the 150mg and 300mg strength tablets is called Opadry II Lt Yellow; and the entire film-coat for the 200mg strength tablets is called Opadry II Lt White. Appropriate justification for the inclusion of each excipient has been provided.

All excipients constituting the tablet cores comply with their respective European Pharmacopoeia monographs. The coating materials, Opadry II Lt Orange, Opadry II Lt Yellow, and Opadry II White, comply with satisfactory in-house specifications. Satisfactory Certificates of Analysis have been provided for all excipients.

There are two excipients used that contain material of animal or human origin – magnesium stearate and lactose monohydrate:

Magnesium stearate – the applicant has provided an acceptable Certificate of Suitability.

Lactose monohydrate - the applicant has provided a declaration that milk used in the production of lactose monohydrate is sourced from healthy animals under the same conditions as that for human consumption.

There were no novel excipients used and no overages.

Three types of primary packaging are proposed for the marketed product:

- (1) polyvinyl chloride (PVC) / polyethylene (PE) / Aclar - aluminium blisters
- (2) polyvinyl chloride (PVC) / polyvinylidene chloride (PVdC) / aluminium blisters
- (3) round white high density polyethylene (HDPE) containers with child-resistant polypropylene closures

The tablets are packed in the blisters / HDPE containers, which are placed with the Patient Information Leaflet (PIL) into cardboard outer cartons. All tablet strengths are packaged in blister pack sizes of 1, 10, 20, 30, 50, 60, 90 and 100 (5 x 20); the 25mg strength tablets are additionally packed in a blister pack size of 6 tablets. All tablet strengths are also packaged in hospital blister packs. The 25mg, 100mg and 200mg strength tablets are available in hospital blister packs of 50 tablets; the 150mg and 300mg strength tablets are available in hospital blister packs of 50, 120, 180 and 240 tablets. All the different strength tablets are packaged in HDPE container pack sizes of 100 and 250 tablets. The Marketing Authorisation (MA) Holder has stated that not all pack sizes may be marketed.

Specifications and Certificates of Analysis for all packaging components used have been provided. These are satisfactory. All primary product packaging complies with EU legislation, Directive 2002/72/EC (as amended), and is suitable for contact with foodstuffs.


II.2 Drug Substance

Quetiapine fumarate

INN: Quetiapine fumarate

Chemical Name: Bis[2-(2-[4-(dibenzo[b,f]-[1,4]-thiazepin-11-yl-1)piperazinyl]ethoxy) ethanol], fumarate

Structure:



Molecular formula: $(C_{21}H_{25}N_3O_2S)_2, C_4H_4O_4$

Molecular weight: 883.1 g/mol

CAS No: 111974-69-7 (base); 111974-72-2 (fumarate salt)

Physical form: White to off- white crystalline powder.

Solubility: Slightly soluble in water, sparingly soluble in pH 3 buffer. Soluble in 0.1 N HCl. Slightly soluble in the organic solvents, methanol, ethanol and acetone.

Stereochemistry Quetiapine fumarate is achiral and only one polymorphic form of quetiapine fumarate is known to exist.

The active substance, quetiapine fumarate, is not the subject of a European Pharmacopoeia (EP) monograph.

The active substance was sourced from two alternative manufacturers. Synthesis of the active substance from the designated starting materials has been adequately described and appropriate in-process controls and intermediate specifications are applied. Satisfactory specifications are in place for all starting materials and reagents and these are supported by relevant Certificates of Analysis. Confirmation has been provided that the raw materials, intermediates and auxiliary agents used in synthesis of the active are not of animal, biological or genetically modified origin, and therefore comply with the TSE requirements.

Appropriate active substance specifications have been provided for the active substance sourced from both manufacturers. Analytical methods have been appropriately validated and are satisfactory for ensuring compliance with the relevant specifications. Batch analysis data are provided and comply with the proposed specification. Satisfactory Certificates of Analysis have been provided for reference standards used by the active substance manufacturers during validation studies.

The active substance is stored in appropriate packaging. Specifications and Certificates of Analysis have been provided for the packaging materials used. The primary packaging in

direct contact with the active substance satisfies Directive 2002/72/EC (as amended), and is suitable for contact with foodstuffs.

Appropriate stability data have been generated by both active substance manufacturers for active substance stored in the proposed commercial packaging. These data demonstrate the stability of the active substance and support a suitable retest period.

II.3 Medicinal Product

Pharmaceutical development

Details of the pharmaceutical development of the drug products have been supplied and are satisfactory.

Comparative dissolution and impurity data for each strength were provided for the generic tablets and appropriate comparator products (including originator products) sourced from various markets. The dissolution and impurity profiles were found to be similar, with all impurities within the specification limits.

Manufacture of the products

A description and flow-chart of the manufacturing method has been provided.

In-process controls are appropriate considering the nature of the product and the method of manufacture. Process validation studies have been conducted and are satisfactory.

Product Specifications

The finished product specifications are provided for both release and shelf life and are satisfactory; they provide an assurance of the quality and consistency of the finished products. Acceptance limits have been justified with respect to conventional pharmaceutical requirements and, where appropriate, safety. Test methods have been described and have been adequately validated, as appropriate. Batch data have been provided and comply with the release specifications. Certificates of Analysis have been provided for any reference standards used.

Stability of the products

Finished product stability studies have been conducted in accordance with current guidelines and results were within the proposed specification limits. Based on the results, a shelf-life of 3 years has been set, which is satisfactory. There are no special storage instructions.

II.4 Discussion on chemical, pharmaceutical and biological aspects

The drug products correspond to the current EU definition of a generic medicinal product because they comply with the criteria of having the same qualitative and quantitative composition in terms of the active substance and pharmaceutical form. On this basis, and considering the bioequivalence data provided, the applicant's claim that Quetiapine 25mg film-coated tablets is a generic medicinal product of Seroquel 25mg tablets (AstraZeneca, UK) appears justified.

As the test products, Quetiapine 25mg, 100mg, 150mg, 200mg and 300mg film-coated tablets meet the criteria specified in the Note for Guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98), the results and conclusions of the bioequivalence study on the 25mg strength were extrapolated to the 100mg, 150mg, 200mg and 300mg strength tablets.

All pharmaceutical issues have been resolved and the quality grounds for these applications are considered adequate. Marketing Authorisations were, therefore, granted.

III Non-clinical aspects

Specific non-clinical studies have not been performed, which is acceptable for these applications for generic versions of a product that has been licensed for over 10 years. The non-clinical overview provides a satisfactory review of the pharmacological and toxicological properties of quetiapine, which is a widely used and well-known active substance.

IV Clinical aspects

IV.1 Introduction

The clinical pharmacology of quetiapine is well known. No novel pharmacodynamic data are supplied or required for this application.

IV.2 Pharmacokinetics

The applicant has conducted a single bioequivalence study comparing the pharmacokinetic profiles of Quetiapine 25mg film-coated tablets (test) and Seroquel 25mg tablets, AstraZeneca, UK (reference). The study was of an appropriate design and was conducted to principles of good clinical practice. The lowest dose of 25 mg was selected because of safety concerns if healthy subjects were used for 100 mg (or higher strength) testing. This was considered satisfactory.

This was a randomised, two-treatment, two-period, two sequence, single dose crossover bioavailability and bioequivalence study conducted in 40 (39 completed) healthy adult human male subjects under fasting conditions (at least 10 hours).

A single dose of the investigational products was administered orally, with water, to each subject in each period, after an overnight fast of 10 hours. A satisfactory washout period of 7 days was maintained between the two dosing days in each group.

Blood samples were taken at the following times (hours): pre-dose (0.0) and then at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 16 and 24 hours after administration of test or reference product. The samples were extracted and analysed by a validated method.

Bioequivalence of the test product versus the reference product was concluded if the 90% Confidence Intervals fell within the acceptance range of 0.8-1.25 for C_{max} , AUC_{0-t} , and $AUC_{0-\infty}$.

Results:

One subject was withdrawn due to an adverse event (vomiting after period 1). There were 112 adverse events involving 31 subjects, but none of these were considered serious or to have a significant impact on the integrity of the study results.

The summary of the results of the bioequivalence study are tabulated below.

Pharmacokinetic results for a randomised single dose 2-way crossover study between the test and reference products. n=39 healthy subjects, dosed fasted; t=24 hours. Wash-out period: 7 days

	Quetiapine 25 mg (Test)	Seroquel 25 mg (Reference)	Test/Ref (90% CI)

AUC_{0-t} (ng.hr/ml)	246.08	252.01	91.25% to 104.49%
AUC_{0-inf} (ng.hr/ml)	256.29	262.47	91.39% to 104.33%
C_{max} (ng/ml)	69.73	69.37	92.87% to 108.81%

Conclusion on Bioequivalence

The results of the bioequivalence study show that the test product and reference product are bioequivalent, under fasting conditions, as the confidence intervals for C_{max}, AUC_{0-t}, and AUC_{0-∞} fall within the acceptance criteria ranges of 80-125% in line with current CHMP guidelines.

Satisfactory justification is provided for a bio-waiver for Quetiapine 100mg, 150mg, 200mg and 300mg tablets. As Quetiapine 25mg, 100mg, 150mg, 200mg and 300mg film-coated tablets meet the criteria specified in the Note for Guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98), the results and conclusions of the bioequivalence study on the 25mg strength were extrapolated to the 100mg, 150mg, 200mg and 300mg strength products.

IV.3 Pharmacodynamics

No new pharmacodynamics data are required for these applications and none have been submitted.

IV.4 Clinical efficacy

No new data have been submitted and none are required. Efficacy is reviewed in the clinical overview. The efficacy of quetiapine is well-established from its extensive use in clinical practice.

IV.5 Clinical safety

No new data have been submitted and none are required for applications of this type. Safety is reviewed in the clinical overview. The safety profile of quetiapine is well-known.

IV.6 Pharmacovigilance System

A satisfactory pharmacovigilance system has been provided to monitor the safety of this product.

IV.7 Discussion on the clinical aspects

The bioequivalence study was of an appropriate design and demonstrates the bioequivalence of the test (Quetiapine 25mg film-coated tablets) and reference (Seroquel 25mg tablets, AstraZeneca, UK) products within general acceptance limits. The results and conclusions of the bioequivalence study on the 25mg strength were extrapolated to the 100mg, 150mg, 200mg and 300mg strength products.

Sufficient clinical information has been submitted to support these applications. Marketing Authorisations were, therefore, granted on medical grounds.

V User consultation

A package leaflet has been submitted to the MHRA along with results of consultations with target patient groups ("user testing"), in accordance with Article 59 of Council Directive 2001/83/EC. The results indicate that the package leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains.

VI Overall conclusion, benefit/risk assessment and recommendation

QUALITY

The important quality characteristics of Quetiapine 25mg, 100mg, 150mg, 200mg and 300mg film-coated tablets are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance.

NON-CLINICAL

No new non-clinical data were submitted and none are required for applications of this type.

CLINICAL


Bioequivalence has been demonstrated between the applicant's Quetiapine 25mg film-coated tablets, and the reference product, Seroquel 25mg tablets (PL 17901/0038; AstraZeneca, UK).

As Quetiapine 25mg, 100mg, 150mg, 200mg and 300mg film-coated tablets were deemed to meet the criteria specified in the Note for Guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98), the results and conclusions of the bioequivalence study on the 25mg strength were extrapolated to the 100mg, 150mg, 200mg and 300mg tablet strengths, and no separate bioequivalence studies were necessary.

No new or unexpected safety concerns arose from these applications.

The Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and labelling are satisfactory, in line with current guidelines and consistent with the reference products. In accordance with Directive 2012/84/EU, the current approved UK versions of the SmPCs and PILs for these products are available on the MHRA website.


The current approved UK labelling is presented below:




<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>
<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>
<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>
<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>	<p>Quetiapine 25 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75004-B</p>



<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	
<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>
<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>
<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>	<p>Quetiapine 100 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75007-B</p>



<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	
<p>e 150 mg ed Tablets pine TEVA UK Ltd 19-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>④ Quetiapir Film-coat Queti MA Holder: 750</p>
<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	
<p>e 150 mg ed Tablets pine TEVA UK Ltd 19-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>⑤ Quetiapir Film-coat Queti MA Holder: 750</p>
<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	
<p>e 150 mg ed Tablets pine TEVA UK Ltd 19-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>Quetiapine 150 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75009-B</p>	<p>⑥ Quetiapir Film-coat Queti MA Holder: 750</p>



Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	
e 200 mg ed Tablets pine TEVA UK Ltd 11-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	④ Quetiapin Film-coat Quetic MA Holder: 750
Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	
e 200 mg ed Tablets pine TEVA UK Ltd 11-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	⑤ Quetiapin Film-coat Quetic MA Holder: 750
Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	
e 200 mg ed Tablets pine TEVA UK Ltd 11-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	Quetiapine 200 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75011-B	⑤ Quetiapin Film-coat Quetic MA Holder: 750



<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	
<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>④ Quetiapine Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>
<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	
<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>⑤ Quetiapine Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>
<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	
<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>Quetiapine 300 mg Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>	<p>⑥ Quetiapine Film-coated Tablets Quetiapine MA Holder: TEVA UK Ltd 75013-B</p>

Table of content of the PAR update for MRP and DCP

Steps taken after the initial procedure with an influence on the Public Assessment Report
(Type II variations, PSURs, commitments)

The following table lists a non-safety update to the Marketing Authorisations for these products that has been approved by the MHRA since the products were first licensed. The table includes updates that are detailed in the annex to this PAR. This is not a complete list of the post-authorisation changes that have been made to these Marketing Authorisations.

Scope	Procedure numbers	Product information affected	Date of start of the procedures	Date of end of procedures	Approval / non approval	Assessment report attached Y/N (version)
To update sections 2, 4.2, 4.4, 4.8, 4.9, 5.1, 5.2 of the SmPC in line with EU PSUR Work Sharing Final Summary Assessment Report (Reference Document. Seroquel (quetiapine): NL/H/PSUR/0021/005) and latest Quality Review of Documents (QRD) template. Consequently the leaflet has been updated	UK/H/1228/001-005/IB/038	SmPC and PIL	13/05/2016	02/09/2016	Approved	Yes

Annex 1

Reference: PL 00289/1068-0056; PL 00289/1069-0057; PL 00289/01070-0057;
PL 00289/1071-0059; PL 00289/1072-0057

European Procedure Number: UK/H/1228/001-005/IB/038

Product: Quetiapine 25 mg, 100 mg, 150 mg, 200 mg and 300 mg film-coated tablets

Marketing Authorisation Holder: Teva UK Limited

Active Ingredient: Quetiapine fumarate

Reason:

To update sections 2, 4.2, 4.4, 4.8, 4.9, 5.1, 5.2 of the SmPC in line with EU PSUR Work Sharing Final Summary Assessment Report (Reference Document. Seroquel (quetiapine): NL/H/PSUR/0021/005) and latest Quality Review of Document (QRD) template. Consequently the leaflet has been updated.

Supporting evidence

The applicant has submitted updated sections of the SmPCs and PIL.

Evaluation

The amended sections of the SmPCs and PIL are satisfactory.

Conclusion

The variation procedures were approved on 02 September 2016 and the updated SmPC fragments and the PIL were incorporated into each Marketing Authorisation.

Decision: Grant on 02 September 2016.